| 前收盘价格 | 122.90 |
| 收盘价格 | 122.90 |
| 成交量 | 4,243,043 |
| 平均成交量 (3个月) | 10,199,579 |
| 市值 | 111,089,860,608 |
| 预期市盈率 (P/E Forward) | 166.67 |
| 价格/销量 (P/S) | 37.46 |
| 股市价格/股市净资产 (P/B) | 15.36 |
| 52周波幅 | |
| 利润日期 | 26 Aug 2025 |
| 营业毛利率 | -24.23% |
| 营业利益率 (TTM) | -31.62% |
| 稀释每股收益 (EPS TTM) | -0.660 |
| 季度收入增长率 (YOY) | 29.40% |
| 总债务/股东权益 (D/E MRQ) | 58.52% |
| 流动比率 (MRQ) | 5.15 |
| 营业现金流 (OCF TTM) | -527.62 M |
| 杠杆自由现金流 (LFCF TTM) | -1.11 B |
| 资产报酬率 (ROA TTM) | -4.16% |
| 股东权益报酬率 (ROE TTM) | -8.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | AKESO | - | - |
AIStockmoo 评分
1.5
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.50 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.39 |
| INNOVENT BIO | 161 B | - | 128.90 | 11.07 |
| WUXI BIO | 136 B | - | 30.50 | 2.72 |
| SINO BIOPHARM | 126 B | 1.15% | 29.38 | 3.35 |
| JUNSHI BIO | 33 B | - | - | 3.43 |
|
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Growth |
| 内部持股比例 | 24.58% |
| 机构持股比例 | 28.47% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合